Navigation Links
NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction
Date:4/7/2011

ly difficult in diabetics, largely because the standard 12L ECG is often inaccurate, inconclusive or non-diagnostic in this patient group.  To address this problem, investigators at the University of Kansas Medical Center, in collaboration with NewCardio physician-scientists, obtained detailed clinical and 12L ECG data on 155 consecutive diabetic patients with suspected AMI, and evaluated the diagnostic performance of my3KG in this patient group.  

The study showed that my3KG had 42% greater sensitivity than expert cardiologist interpretation of 12L ECG for early detection of AMI, with equal or better specificity.  Based on these important results, NewCardio believes use of my3KG in this patient group may facilitate more accurate and timely diagnosis of AMI in diabetic patients, thereby improving clinical outcomes.

NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG.  NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI.  In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities).  Accordingly, the Company believes that its innovative my3kg solution will substantially improve diagnostic timing and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients.  The my3KG is not currently marketed for sale in the U.S.  The Company intends to file an application for 510(k) approval with the FDA in 2011/2012.

About the American Diabetes Association

The ADA is a volunteer-driven organization based in Alexandria, VA, with affiliate offices across the U.S.  The mission of t
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NewCardio Announces Positive Results From Third Clinical Validation Study
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Leadership to Present Two Abstracts at ISCE Conference
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio CEO Increases Equity Position
8. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
9. NewCardio Announces Financial Results for Its 2010 Third Quarter
10. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
11. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) ... and medical device R&D outsourcing company with operations in ... , today announced that it will release financial results ... Stock Exchange closes on Wednesday, August 13, 2014 (which will ... release will be available on the investor relations section of ...
(Date:7/22/2014)... July 22, 2014  UL (Underwriters Laboratories), a ... U.S. Food and Drug Administration (FDA) has recognized ... for medical devices incorporating lithium or nickel-based batteries. ... for Household and Commercial Batteries, and UL 1642 ... Consensus standards are standards recognized by the ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... 6, 2011 A new study , released ... the United States witnessed opiate prescriptions for chronic abdominal ... Michael Lowenstein, co-medical director for the Waismann Method, an ... that this increase signals the gaining popularity of prescription ...
...  Glowpoint, Inc. (OTCBB: GLOW), a leading global provider of ... a leading global pharmaceutical services company has signed with ...   This new Glowpoint customer is the ... clinical, commercial, consulting and capital solutions. The firm has ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3Global Pharmaceutical Services Company Turns to Glowpoint's OpenVideo™ Cloud 2
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... microplate washers available to handle ... cell-based assays. Embla 384 Cell ... have been optimized to avoid ... robotic compatible and have been ...
ELISA Microplate Washer, Manual...
Medicine Products: